Page updated ·next FDA decision on the calendar·Data as of Nov 19, 2026 12:24 AM ET
sotagliflozin SONATA-HCM (Phase 3) is a Lexicon Pharmaceuticals, Inc. program in symptomatic hypertrophic cardiomyopathy. Its next catalyst is a Readout in Q1 2027.
Indication under review: Symptomatic hypertrophic cardiomyopathy. Sponsor: Lexicon Pharmaceuticals, Inc. (LXRX). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
When is sotagliflozin SONATA-HCM (Phase 3)'s next FDA decision or readout?
The next tracked catalyst for sotagliflozin SONATA-HCM (Phase 3) is a Readout in Q1 2027.
What happened at sotagliflozin SONATA-HCM (Phase 3)'s most recent FDA decision?
No FDA decision for sotagliflozin SONATA-HCM (Phase 3) is in our archive yet.
What is sotagliflozin SONATA-HCM (Phase 3) used for?
In our records sotagliflozin SONATA-HCM (Phase 3) is under review or in development for Symptomatic hypertrophic cardiomyopathy.
Who makes sotagliflozin SONATA-HCM (Phase 3)?
Lexicon Pharmaceuticals, Inc. (LXRX).
Where does this data come from?
FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.
Facts and dates only; not investment advice. Verify against primary FDA, SEC
and company filings. pdufa.bio is not affiliated with the FDA.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.